243 related articles for article (PubMed ID: 10362351)
1. Inhibition of E6 induced degradation of p53 is not sufficient for stabilization of p53 protein in cervical tumour derived cell lines.
Mantovani F; Banks L
Oncogene; 1999 Jun; 18(22):3309-15. PubMed ID: 10362351
[TBL] [Abstract][Full Text] [Related]
2. Alternatively spliced HPV-18 E6* protein inhibits E6 mediated degradation of p53 and suppresses transformed cell growth.
Pim D; Massimi P; Banks L
Oncogene; 1997 Jul; 15(3):257-64. PubMed ID: 9233760
[TBL] [Abstract][Full Text] [Related]
3. Induction of the p53-target gene GADD45 in HPV-positive cancer cells.
Butz K; Whitaker N; Denk C; Ullmann A; Geisen C; Hoppe-Seyler F
Oncogene; 1999 Apr; 18(14):2381-6. PubMed ID: 10327059
[TBL] [Abstract][Full Text] [Related]
4. The presence of human papillomavirus-16/-18 E6, p53, and Bcl-2 protein in cervicovaginal smears from patients with invasive cervical cancer.
Pillai MR; Halabi S; McKalip A; Jayaprakash PG; Rajalekshmi TN; Nair MK; Herman B
Cancer Epidemiol Biomarkers Prev; 1996 May; 5(5):329-35. PubMed ID: 9162297
[TBL] [Abstract][Full Text] [Related]
5. p53-independent growth regulation of cervical cancer cells by the papillomavirus E6 oncogene.
Spitkovsky D; Aengeneyndt F; Braspenning J; von Knebel Doeberitz M
Oncogene; 1996 Sep; 13(5):1027-35. PubMed ID: 8806692
[TBL] [Abstract][Full Text] [Related]
6. HPV-18 E6*I protein modulates the E6-directed degradation of p53 by binding to full-length HPV-18 E6.
Pim D; Banks L
Oncogene; 1999 Dec; 18(52):7403-8. PubMed ID: 10602499
[TBL] [Abstract][Full Text] [Related]
7. Effect of BPV1 E2-mediated inhibition of E6/E7 expression in HPV16-positive cervical carcinoma cells.
Moon MS; Lee CJ; Um SJ; Park JS; Yang JM; Hwang ES
Gynecol Oncol; 2001 Feb; 80(2):168-75. PubMed ID: 11161855
[TBL] [Abstract][Full Text] [Related]
8. A plant lignan, 3'-O-methyl-nordihydroguaiaretic acid, suppresses papillomavirus E6 protein function, stabilizes p53 protein, and induces apoptosis in cervical tumor cells.
Allen KL; Tschantz DR; Awad KS; Lynch WP; DeLucia AL
Mol Carcinog; 2007 Jul; 46(7):564-75. PubMed ID: 17393435
[TBL] [Abstract][Full Text] [Related]
9. HPV 16-E6-mediated degradation of intrinsic p53 is compensated by upregulation of p53 gene expression in normal cervical keratinocytes.
Kawamata Y; Mitsuhashi A; Unno Y; Kado S; Shino Y; Uesugi K; Eguchi O; Ishii J; Seki K; Sekiya S; Shirasawa H
Int J Oncol; 2002 Sep; 21(3):561-7. PubMed ID: 12168100
[TBL] [Abstract][Full Text] [Related]
10. Specific HIV protease inhibitors inhibit the ability of HPV16 E6 to degrade p53 and selectively kill E6-dependent cervical carcinoma cells in vitro.
Hampson L; Kitchener HC; Hampson IN
Antivir Ther; 2006; 11(6):813-25. PubMed ID: 17310826
[TBL] [Abstract][Full Text] [Related]
11. The role of TP53 in Cervical carcinogenesis.
Tommasino M; Accardi R; Caldeira S; Dong W; Malanchi I; Smet A; Zehbe I
Hum Mutat; 2003 Mar; 21(3):307-12. PubMed ID: 12619117
[TBL] [Abstract][Full Text] [Related]
12. The role of the E6-p53 interaction in the molecular pathogenesis of HPV.
Thomas M; Pim D; Banks L
Oncogene; 1999 Dec; 18(53):7690-700. PubMed ID: 10618709
[TBL] [Abstract][Full Text] [Related]
13. Interactions of HPV E6 and E7 oncoproteins with tumour suppressor gene products.
Münger K; Scheffner M; Huibregtse JM; Howley PM
Cancer Surv; 1992; 12():197-217. PubMed ID: 1322242
[TBL] [Abstract][Full Text] [Related]
14. Neocarzinostatin induces an effective p53-dependent response in human papillomavirus-positive cervical cancer cells.
Bañuelos A; Reyes E; Ocadiz R; Alvarez E; Moreno M; Monroy A; Gariglio P
J Pharmacol Exp Ther; 2003 Aug; 306(2):671-80. PubMed ID: 12750435
[TBL] [Abstract][Full Text] [Related]
15. Role of a p53 polymorphism in the development of human papillomavirus-associated cancer.
Storey A; Thomas M; Kalita A; Harwood C; Gardiol D; Mantovani F; Breuer J; Leigh IM; Matlashewski G; Banks L
Nature; 1998 May; 393(6682):229-34. PubMed ID: 9607760
[TBL] [Abstract][Full Text] [Related]
16. DNA damage induced p53 mediated transcription is inhibited by human papillomavirus type 18 E6.
Gu Z; Pim D; Labrecque S; Banks L; Matlashewski G
Oncogene; 1994 Feb; 9(2):629-33. PubMed ID: 8290274
[TBL] [Abstract][Full Text] [Related]
17. A single-codon mutation converts HPV16 E6 oncoprotein into a potential tumor suppressor, which induces p53-dependent senescence of HPV-positive HeLa cervical cancer cells.
Ristriani T; Fournane S; Orfanoudakis G; Travé G; Masson M
Oncogene; 2009 Feb; 28(5):762-72. PubMed ID: 19015633
[TBL] [Abstract][Full Text] [Related]
18. High-risk HPV E6 oncoproteins assemble into large oligomers that allow localization of endogenous species in prototypic HPV-transformed cell lines.
García-Alai MM; Dantur KI; Smal C; Pietrasanta L; de Prat-Gay G
Biochemistry; 2007 Jan; 46(2):341-9. PubMed ID: 17209544
[TBL] [Abstract][Full Text] [Related]
19. Immunohistochemical co-expression of human papillomavirus type 16/18 transforming (E6) oncoprotein and p53 tumour suppressor gene proteins in oesophageal cancer.
Agarwal SK; Chatterji A; Bhambhani S; Sharma BK
Indian J Exp Biol; 1998 Jun; 36(6):559-63. PubMed ID: 9731468
[TBL] [Abstract][Full Text] [Related]
20. Functional consequences of directed mutations in human papillomavirus E6 proteins: abrogation of p53-mediated cell cycle arrest correlates with p53 binding and degradation in vitro.
Slebos RJ; Kessis TD; Chen AW; Han SM; Hedrick L; Cho KR
Virology; 1995 Apr; 208(1):111-20. PubMed ID: 11831691
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
